Iradimed Retained Earnings Total Equity Over Time
| IRMD Stock | USD 53.93 0.35 0.65% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Iradimed Performance and Iradimed Correlation. Iradimed |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iradimed. If investors know Iradimed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iradimed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0) | Dividend Share 0.45 | Earnings Share 1.46 | Revenue Per Share 5.635 | Quarterly Revenue Growth 0.11 |
The market value of Iradimed is measured differently than its book value, which is the value of Iradimed that is recorded on the company's balance sheet. Investors also form their own opinion of Iradimed's value that differs from its market value or its book value, called intrinsic value, which is Iradimed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iradimed's market value can be influenced by many factors that don't directly affect Iradimed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iradimed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Iradimed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iradimed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Retained Earnings Total Equity Analysis
Compare Iradimed and related stocks such as Pulmonx Corp, Orthofix Medical, and Neuropace Retained Earnings Total Equity Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LUNG | (242.7 M) | (242.7 M) | (242.7 M) | (242.7 M) | (242.7 M) | (242.7 M) | (242.7 M) | (242.7 M) | (242.7 M) | (242.7 M) | (242.7 M) | (291.4 M) | (350.3 M) | (315.3 M) | (331.1 M) |
| OFIX | 97.3 M | 97.3 M | 114.8 M | 0.0 | 65.4 M | 62.6 M | 64.2 M | 70.4 M | 87.1 M | 57.7 M | 59.4 M | 21 M | 1.3 M | 1.1 M | 1.1 M |
| NPCE | (423.8 M) | (423.8 M) | (423.8 M) | (423.8 M) | (423.8 M) | (423.8 M) | (423.8 M) | (423.8 M) | (423.8 M) | (423.8 M) | (423.8 M) | (423.8 M) | (470.9 M) | (423.8 M) | (445 M) |
| ITGR | 152.5 M | 152.5 M | 147.7 M | 184 M | 239.4 M | 231.9 M | 109.1 M | 176.1 M | 344.5 M | 440.3 M | 517.5 M | 614.3 M | 680.7 M | 782.8 M | 821.9 M |
| GKOS | (196.6 M) | (196.6 M) | (196.6 M) | (196.6 M) | (196.6 M) | (196.6 M) | (192.1 M) | (192.2 M) | (205.1 M) | (189.7 M) | (310.1 M) | (365.2 M) | (464.4 M) | (418 M) | (438.9 M) |
| CNMD | 354.4 M | 354.4 M | 377.9 M | 395.9 M | 406.1 M | 414.5 M | 406.9 M | 440.1 M | 464.9 M | 470.8 M | 457.4 M | 496.6 M | 412.6 M | 474.5 M | 467.3 M |
| LIVN | (14.6 M) | (14.6 M) | (14.6 M) | (14.6 M) | (14.6 M) | (14.6 M) | (14.6 M) | (39.7 M) | (251.6 M) | (752.4 M) | (752.4 M) | (897.8 M) | (897.8 M) | (808 M) | (767.6 M) |
| ELMD | 2 M | 2 M | 710.8 K | (577.8 K) | 514.7 K | 2.7 M | 5 M | 6.9 M | 9.5 M | 13.7 M | 14.9 M | 15.8 M | 18.8 M | 21.6 M | 22.7 M |
| KIDS | (103.1 M) | (103.1 M) | (103.1 M) | (103.1 M) | (103.1 M) | (103.1 M) | (103.1 M) | (103.1 M) | (115.1 M) | (128.8 M) | (161.8 M) | (178 M) | (176.8 M) | (159.1 M) | (167 M) |
| SRDX | 64.4 M | 74.6 M | 91 M | 0.0 | 0.0 | 98.1 M | 102.1 M | 97.6 M | 110.7 M | 111.8 M | 116.1 M | 88.8 M | 88.8 M | 102.1 M | 87.6 M |
| SGHT | (153 M) | (153 M) | (153 M) | (153 M) | (153 M) | (153 M) | (153 M) | (153 M) | (153 M) | (153 M) | (153 M) | (153 M) | (239.2 M) | (215.3 M) | (226.1 M) |
| ANIK | 34.3 M | 34.3 M | 0.0 | 0.0 | 104.9 M | 0.0 | 168.2 M | 199.5 M | 218.2 M | 245.4 M | 221.4 M | 225.6 M | 210.7 M | 242.3 M | 149.3 M |
Iradimed and related stocks such as Pulmonx Corp, Orthofix Medical, and Neuropace Retained Earnings Total Equity description
The portion of total equity that consists of earnings retained by the company, reinvested in its core business or used to pay debt.My Equities
My Current Equities and Potential Positions
| Iradimed Co | IRMD |
Specialization | Health Care, Health Care Equipment & Services |
| Location | Florida; U.S.A |
| Exchange | NASDAQ Exchange |
USD 53.93
Check out Iradimed Performance and Iradimed Correlation. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Iradimed technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.